Geographic atrophy(GA)secondary to age-related macular degeneration(AMD)lacks effective treatment at present.There is growing evidence that the onset and progression of AMD-induced GA is closely related to complement cascade dysregulation.As part of the innate immune system,the complement system plays an important role in maintaining homeostasis in the human body,and overactivation of complement will disrupt this balance and promote the progression of age-related macular degeneration.Based on this finding,C1q,C3,C5,complement factors B,D,H,I and membrane attack complex can be the potential targets for complement activation pathways;and the corresponding drug forms will be biological macromolecules,chemical small molecules and gene therapy agents.Now,a variety of drugs for the treatment of AMD-induced GA have entered clinical trials,and this article reviews the progress of clinical trials of complement therapy for GA and its safety and efficacy.
维普
万方数据